End-Stage Renal Disease (ESRD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 End-stage renal disease (ESRD) is the irreversible stage of kidney impairment that cannot be controlled by conservative management alone and requires dialysis or kidney transplantation to maintain life. There are two levels of kidney impairment that can lead to ESRD: acute and chronic. End-stage renal disease (ESRD) implies chronic renal failure (CRF) of a degree (i.e., glomerular filtration rate, GFR<10–12 mL/min) such that life cannot be sustained long-term without dialysis. In contrast to acute kidney failure, chronic kidney failure is a permanent condition that leads to a progressive decline in renal function. Once it occurs, the kidneys cannot be made to function properly again, even when an inciting event has been corrected. CRF may exist for 10 to 20 years before progressing to ESRD. Over 70% of late-stage chronic kidney disease cases result from prolonged diabetes mellitus or hypertension. Glomerulonephritis, cystic diseases, and other urologic diseases account for another 12%, and 15% of patients have other or unknown causes of CRF. Long-term complications of chronic kidney disease (CKD) include a high risk of morbidity and mortality of cardiovascular disease compared to the general population. Mortality attributable to a cardiovascular cause accounts for 45% of all deaths of patients receiving dialysis. Between 80% and 90% of patients with CKD die of cardiovascular disease before reaching the need for dialysis. The precise biologic mechanisms for this are unclear. However, they may have to do with the uremic milieu, underlying coexistent comorbidities, and a hesitancy to perform investigative procedures in patients with chronic kidney disease.

·       End-stage renal disease (ESRD) incidence varies from 351 to 421 cases per million population.

 

Thelansis’s “End-Stage Renal Disease (ESRD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential End-Stage Renal Disease (ESRD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of End-Stage Renal Disease (ESRD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

End-Stage Renal Disease (ESRD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: End-Stage Renal Disease (ESRD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: End-Stage Renal Disease (ESRD), End-Stage Renal Disease (ESRD) market outlook, End-Stage Renal Disease (ESRD) competitive landscape, End-Stage Renal Disease (ESRD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)